DURACLON indications and usage: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 8: | Line 8: | ||
Duraclon is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see Clinical Trials). | Duraclon is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see Clinical Trials). | ||
The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DURACLON (CLONIDINE HYDROCHLORIDE) INJECTION, SOLUTION [MYLAN INSTITUTIONAL LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c126bb8-732a-4949-8754-2f50b5543638 | publisher = | date = | accessdate = | The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DURACLON (CLONIDINE HYDROCHLORIDE) INJECTION, SOLUTION [MYLAN INSTITUTIONAL LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c126bb8-732a-4949-8754-2f50b5543638#i4i_clinical_pharmacology_id_a61d4026-7aae-4211-9bb5-332675db4e46 | publisher = | date = | accessdate = 6 February 2014 }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 16:44, 6 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
For patient information, click here.
Indications and Usage
Duraclon is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see Clinical Trials).
The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS).[1]
References
- ↑ "DURACLON (CLONIDINE HYDROCHLORIDE) INJECTION, SOLUTION [MYLAN INSTITUTIONAL LLC]". Retrieved 6 February 2014.